As of November 9, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Scilex Holding Company. The largest reported stake is SCLX Stock Acquisition JV LLC's, at 11.4%. 4 filings are on record since August 14, 2025 (Schedule 13D/A, July 7, 2026).
Sell to companies like Scilex Holding Company? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: SCLX Stock Acquisition JV LLC · Sole voting: 30,029,378 · Shared voting: 0 · Sole dispositive: 30,029,378 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-07
- · Holder: Oramed Pharmaceuticals Inc. · Percent: 4.9% · SCHEDULE 13G/A
- · Holder: Oramed Pharmaceuticals Inc. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Oramed Pharmaceuticals Inc. · Percent: 9.9% · SCHEDULE 13G/A
Scilex Holding Company has 4 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| SCLX Stock Acquisition JV LLC | 11.4% | 30,029,378 | SCHEDULE 13D/A, 2026-07-07 | 2026-07-03 |
| Oramed Pharmaceuticals Inc. | 4.9% | 437,510 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
Holding shares or following this stake? See who's behind Scilex Holding Company and the warning signs.
Free to see. No signup.
Keep reading
More on Scilex Holding Company and the records around it.
Scilex Holding Company elsewhere on the record
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Oramed Pharmaceuticals Inc. also filed stake reports on 2 other companies: Nano Dimension Ltd. (Jul 2026), Lifeward Ltd. (May 2026)
Watch Scilex Holding Company
Get an email when Scilex Holding Company files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Scilex Holding Company?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Scilex Holding Company: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Scilex Holding Company covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| SCLX Stock Acquisition JV LLC | 30,029,378 | 0 | 30,029,378 | 0 | SCHEDULE 13D/A, 2026-07-07 |
The latest filing identifies Scilex Holding Company by CUSIP 80880W205 and gives its principal executive office as 960 San Antonio Road, Palo Alto, CA 94303 (SCHEDULE 13D/A, 2026-07-07).
Purpose of Transaction (Item 4)
SCLX Stock Acquisition JV LLC
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On April 15, 2025, the Issuer effected a reverse stock split of the Common Stock at a ratio of 1-for-35 (the "Reverse Stock Split"). The share information in this Amendment No. 6 reflects the effect of the Reverse Stock Split. On July 3, 2026, the Reporting Person entered into a letter agreement (the "Letter Agreement") with the Issuer and Quantum Scan Holdings, Inc. ("Q Scan"), pursuant to which the Reporting Person transferred 500,000 shares of Common Stock held by the Reporting Person to Q Scan in exchange for shares of common stock of Q Scan. The price at which such shares are being transferred to Q Scan will be based on the closing price of the shares of Issuer common stock on the Nasdaq Capital Market on the last trading day immediately prior to the transfer of such shares pursuant to the Letter Agreement.Item 4 of the SCHEDULE 13D/A filed 2026-07-07
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Oramed Pharmaceuticals Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Oramed Pharmaceuticals Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-02-13 | Oramed Pharmaceuticals Inc. | 4.9% | SCHEDULE 13G/A |
| 2026-07-07 | SCLX Stock Acquisition JV LLC | 11.4% | SCHEDULE 13D/A |
Questions about who owns Scilex Holding Company
Who owns Scilex Holding Company?
On this page, one holder's latest ownership filing reports 5% or more of Scilex Holding Company: SCLX Stock Acquisition JV LLC (11.4%, Schedule 13D/A, filed 2026-07-07).
When did SCLX Stock Acquisition JV LLC buy into Scilex Holding Company?
The filings give report dates, not purchase dates. The earliest filing from SCLX Stock Acquisition JV LLC on this page is the Schedule 13D/A, filed 2026-07-07, reporting 11.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Scilex Holding Company
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 14, 2025 | Form D, private offering | $2.69M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Scilex Holding Company. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.